Dr. Clay Siegall is the Chief Executive Officer at Seattle Genetics. He is also the founder of the company. Based in Bothell City in the State of Washington, Seattle Genetics is a leading biotechnology solutions provider that dedicates itself to the development of targeted therapy medication for disease types that have not seen significant mortality improvements in several years. Dr. Clay Siegall is a well-educated individual especially in his field of expertise. Dr. Siegall graduated from the University of Maryland with a Bachelor’s of Science in Zoology. He also holds a Doctor of Philosophy in genetics from George Washington University.
Ever since he founded Seattle Genetics on July 15, 1997, Dr. Siegall has consciously and progressively steered the firm to the summit of the targeted therapy industry. They developed the first FDA-approved antibody-drug conjugate, which now has multiple approved indications. They have also developed a stable pipeline of drugs and an array of strategic partnerships with manufacturers of medicines such as Bayer, Genentech, Pfizer among several others just to mention a few. This, in essence, shows that Dr. Siegall is not done yet, going into the future, Seattle Genetics has positioned itself to be the go-to industry leaders when it comes to matters cancer treatment by use of targeted therapy drugs.
Thanks to Dr. Siegall’s able leadership, Seattle Genetics has grown from a small startup with just a minimal team of scientists to be one of the most sought-after authorities in the cancer research industry. Motivated and inspired by the love of medicine from a tender age, Dr. Siegall was always fascinated by the use of the power of technology to overcome disease and as a result saving lives. His interest was further drawn to cancer treatment while studying Zoology at the University of Maryland after one of his family members got ill and almost died not from cancer but from the brutal treatment regimen of chemotherapy. Dr. Siegall believes that the days of using systematic chemotherapies are over and that it is about time we welcomed the most efficient and effective and more tolerable way of cancer treatment – the use of targeted therapy drugs.